With decades of experience across various organizations, ClinDatrix staff bring great expertise in conducting clinical trials spanning all phases (I-III) in various cardiovascular conditions. Our extensive research includes pivotal studies on the prevention of myocardial infarction (MI) and stroke, HIV cardiovascular risk reduction, bifurcated stent grafts with five-year follow-up, endovascular aneurysms, abdominal aortic aneurysms, coronary artery disease, transmyocardial revascularization, and blood loss monitoring.
We have successfully designed electronic data capture (EDC) databases for intricate protocols related to these cardiovascular diseases. Our proficiency in electronic case report form design, protocol refinement, and clinical trial logistics positions ClinDatrix as a leader in cardiovascular clinical trials.
Key Highlights of ClinDatrix’s Cardiovascular Expertise:
- Agility in Study Management: Our study database launch capabilities enable deployment on our own servers within 5 weeks—significantly faster than the industry standard of 12 weeks—along with protocol adjustments made within 1-2 days instead of weeks.
- Experienced Team: ClinDatrix’s cardiovascular teams average 20 years of experience in the field, ensuring high-level execution and strategic guidance throughout all phases of clinical trials.
- Regulatory Expertise: We have a proven track record of adhering to industry standards and regulatory requirements, ensuring compliance throughout the study process.
ClinDatrix’s comprehensive support guarantees that sponsors achieve their study objectives with precision, bolstered by our commitment to operational excellence and scientific rigor.
Contact ClinDatrix today to discover how our cardiovascular study services can elevate your research initiatives.
ClinDatrix Studies:
Service Codes
BI = Biostatistics
CL = Clinical
DM = Data Management
FS = Full Service
MS = Medical Safety
MW = Medical Writing
RA = Regulatory Affairs
| Phase | Indication | Thera-peutic Area | Services | Number of Sites | Number of Patients |
| 1 | Prevention of MI and Stroke | Cardiovascular | FS | 1 | 18 |
| 2 | HIV Cardiovascular Risk Reduction | Cardiovascular | CL, DM, MW | 1 | 64 |
| IDE | Bifurcated Stent Graft Study with a 5-Year Follow-up | Cardiovascular | BI, DM | 15 | 64 |
| IDE | Endovascular Aneurysms | Cardiovascular | BI, DM | 2 | 15 |
| IDE | Endovascular Aneurysms | Cardiovascular | BI, DM | 8 | 34 |
| IDE | Endovascular Aneurysms | Cardiovascular | BI, DM | 20 | 96 |
| IDE | Abdominal Aortic Aneurysms | Cardiovascular | DM | 3 | 15 |
| IDE | Endovascular Aneurysms | Cardiovascular | DM | 20 | 192 |
| 2 | Coronary Artery Disease | Cardiovascular | DM | 15 | 200 |
| N/A | Transmyocardial Revascularization | Cardiovascular | BI, DM | 6 | 81 |
| Proof of Concept | Blood Loss Monitoring | Cardiovascular | CL, MS, RA | 1 | 20 |
| Phase | Indication | Therapeutic Area | Services | Number of Sites | Number of Patients |
| 1 | Metastatic Cancer | Oncology | FS | 1 | 21 |
| 1 | KRAS Mutant Metastatic Colorectal Cancer | Oncology | BI, DM | 3 | 25 |
| 1 | KRAS Mutant Metastatic Colorectal Cancer | Oncology | BI, DM | 3 | 36 |
| 1 | Advanced Solid Tumors | Oncology | DM | 3 | 27 |
| 1 | Chronic Lymphocytic Leukemia | Oncology | BI, DM | 5 | 10 |
| 1 | Extensive, recurrent, or metastatic sarcoma, melanoma, or carcinoma | Oncology | CL, RA | 20 | 96 |
| 2 | Glioblastoma and Gliosarcoma | Oncology | DM, CL | 1 | 25 |
| 2 | Advanced Pancreatic Adenocarcinoma | Oncology | DM | 2 | 34 |
| 2 | Metastatic Melanoma | Oncology | DM | 1 | 14 |
| 2 | Squamous Cell Carcinoma of the Lung | Oncology | DM | 12 | 32 |
| 3 | Squamous Cell Carcinoma of the Head and Neck | Oncology | BI, CL, DM, MW | 58 | 184 |
| 1/2A | Recurrent Grade IV Glioma | Oncology | FS | 9 | 49 |
| 1B | Malignant Pleural Mesothelioma | Oncology | BI, CL, DM | 5 | 60 |
| 1 | Solid Tumors | Oncology | BI, DM | 5 | 27 |
| 1 | Advanced Solid Tumors or Lymphoma | Oncology | BI, DM | 3 | 107 |
| 1 | Lymphocytic Leukemia | Oncology | BI, DM | 1 | 8 |
| 1 | Lymphocytic Leukemia | Oncology | BI, DM | 1 | 12 |
| 1 | Lymphocytic Leukemia | Oncology | BI, DM | 1 | 2 |
| 1 | Metastatic Solid Tumors | Oncology | BI, DM | 1 | 18 |
| 1 | Advanced Malignancies | Oncology | BI, DM | 2 | 17 |
| 1 | Advanced Malignancies | Oncology | BI, DM | 3 | 25 |
| 1 | Advanced Malignancies | Oncology | BI, DM | 3 | 38 |
| 1 | Oncology | Oncology | BI, CL, DM | 1 | 5 |
| 1 | Chronic Lymphocytic Leukemia | Oncology | BI, DM | 3 | 15 |
| 1/2 | Malignant Gliomas | Oncology | BI, DM | 3 | 18 |
| 1/2 | Advanced Malignancies | Oncology | BI, DM | 2 | 34 |
| 1/2 | Oncology | Oncology | BI | 4 | 20 |
| 1/2A | Basal Cell Carcinoma | Oncology | FS | 3 | 27 |
| 1A/1B | Advanced Metastatic Solid Tumors and NSCLC | Oncology | BI, DM, MS, MW | 7 | 84 |
| 1A/1B | Recurrent Head and Neck Cancer | Oncology | BI, CL, DM, MS, MW | 7 | 40 |
| 2 | Advanced Cancers, including Head, Neck, and Esophageal Cancers | Oncology | BI, DM | 3 | 16 |
| 2 | Bone and Soft Tissue Sarcomas Metastatic to the Lung | Oncology | BI, DM | 4 | 53 |
| 2 | Squamous Cell Carcinoma of the Head and Neck | Oncology | BI, DM | 2 | 14 |
| 2 | Non-Small Cell Lung Cancer accompanied by KRAS or EGFR Activated Tumors | Oncology | BI, DM | 2 | 37 |
| N/A | Oncology | Oncology | BI, DM | 1 | 19 |
| N/A | Oncology | Oncology | BI, DM | 2 | 33 |
| N/A | Oncology | Oncology | BI, DM | 2 | 25 |
| N/A | Oncology | Oncology | BI, DM | 1 | 6 |
| N/A | Oncology | Oncology | BI, DM | 1 | 12 |
| TBD | Prostate Cancer | Oncology | CL | 1 | 167 |